


IASLC 19th World Conference on Lung Cancer Industry Sponsored Symposium

Future options for ALK+ metastatic NSCLC

INVITATION




Tuesday 25 September 07:00–08:00

Room 105, Metro Toronto Convention Centre, North Building,
Toronto, Canada

Light refreshments will be available prior to the symposium





PROGRAMME

Chair's invitation

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology Industry Sponsored Symposium **“Future Options for ALK+ metastatic NSCLC”**.

The landscape for oncogenic-driven metastatic non-small cell lung cancer (NSCLC) is rapidly evolving, and an ever-increasing array of treatments means there are more options than ever before for our patients. However, many challenges remain. One of the key challenges is identifying resistance mutations and developing treatment strategies to manage them.

In this symposium, we will summarise some of the most clinically relevant recent updates in the field of ALK+ NSCLC treatment and discuss the current understanding of resistance mechanisms in ALK+ NSCLC and their implications on optimal treatment sequencing.

We look forward to welcoming you in Toronto for what promises to be both an informative and insightful symposium.

Geoffrey Liu, Chair

Princess Margaret Cancer Centre, Toronto

Programme

Chair: Geoffrey Liu

07:00-07:05	Welcome and introduction	Geoffrey Liu (Canada)
07:05-07:25	Recent advances in treating ALK+ NSCLC: An evolving landscape	Ben Solomon (Australia)
07:25-07:45	Navigating the spectrum of resistance mutations in ALK+ NSCLC: How to identify and treat them	Alice Shaw (USA)
07:45-08:00	Panel Q&A	All, facilitated by Geoffrey Liu

This program was approved by the IASLC 19th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 19th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.